GT Biopharma, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2010 to 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
GT Biopharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2010 to 2023.
- GT Biopharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$3.71M, a 86.2% decline year-over-year.
- GT Biopharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$11.4M, a 22.7% increase year-over-year.
- GT Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$7.6M, a 63.6% increase from 2022.
- GT Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$20.9M, a 64% increase from 2021.
- GT Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$58M, a 105% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)